Clinical utility of current NNRTIs and perspectives of new agents in this class under development.
about
Nevirapine once daily: pharmacology, metabolic profile and efficacy data of the new extended-release formulation.The prevalence of drug resistance among treatment-naïve HIV-1-infected individuals in China during pre- and post- 2004Nanoparticulate drug carriers for delivery of HIV/AIDS therapy to viral reservoir sites.TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.Diphenyl ether non-nucleoside reverse transcriptase inhibitors with excellent potency against resistant mutant viruses and promising pharmacokinetic properties.Prevalence of antiretroviral drug resistance in treated HIV-1 infected patients: under the initiative of access to the NNRTI-based regimen in Thailand.Discovery of a semi-synthesized cyclolignan as a potent HIV-1 non-nucleoside reverse transcriptase inhibitor.Comparing adherence to two different HIV antiretroviral regimens: an instrumental variable analysis.A computational study for rational HIV-1 non-nucleoside Reverse Transcriptase inhibitor selection and discovery of novel allosteric pockets for inhibitor design.Efficacy and resistance of recently developed non-nucleoside reverse transcriptase inhibitors for HIV-1
P2860
Q33850152-E6A9776D-A20E-4154-AE88-A734B2E0F506Q36174668-50B1B791-6B4D-44C8-A69E-7B337D46E1AEQ36583732-CDB9158E-DE96-4334-A840-29A1672CE167Q39771532-AD7FDD84-4E15-447F-A8DB-9CFC39BFBDEFQ42549637-E77B28E4-FB9D-4298-801D-FC1E1CED245DQ46249412-1FE4E087-7874-4100-BCFA-023C23000152Q46855597-6869C0DB-00E8-4B15-9B47-974A90131449Q47560158-52FC7471-9F4E-45E3-BE5D-89550684A4C3Q48631709-888FFAEF-65DC-45EC-AFA5-66A0E0FBAEA7Q50043498-85029A64-9785-448F-8788-F4A3473F162CQ58388963-D893BD3F-A89A-4B92-AC01-356C77032659
P2860
Clinical utility of current NNRTIs and perspectives of new agents in this class under development.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Clinical utility of current NN ...... this class under development.
@ast
Clinical utility of current NN ...... this class under development.
@en
type
label
Clinical utility of current NN ...... this class under development.
@ast
Clinical utility of current NN ...... this class under development.
@en
prefLabel
Clinical utility of current NN ...... this class under development.
@ast
Clinical utility of current NN ...... this class under development.
@en
P2093
P2860
P1476
Clinical utility of current NN ...... this class under development.
@en
P2093
Robert Hamatake
Zhijun Zhang
P2860
P304
P356
10.1177/095632020401500302
P577
2004-05-01T00:00:00Z